Trial Profile
A Phase 1, Open-Label, Single Dose, Randomized, Cross-Over Relative Bioavailability Study Comparing An Oral Liquid Formulation To A Formulated Capsule Of Crizotinib (PF 02341066) In Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Apr 2012
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- 18 Apr 2012 Results presented at the 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 16 Apr 2011 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 21 Mar 2011 Actual initiation date (Mar 2011) added as reported by ClinicalTrials.gov.